Replies to post #168887 on Biotech Values

[zipjet]

Tecfidera - BIIB

However, the predictions of a 50% Tecfidera market share in the US I’m seeing from some analysts seem overblown; I doubt that any single MS drug will ever attain such a threshold.

A pill rather than shots (with the reactions) or infusions is compelling.

My wife is having a lot of mild infections that I assume are due to the immunosuppression of Tecfidera.